Decoding 6 Analyst Evaluations For Prothena Corp
Portfolio Pulse from Benzinga Insights
Prothena Corp (NASDAQ:PRTA) received mixed analyst ratings with a shift towards a more cautious stance in the last quarter. The average 12-month price target was adjusted to $64.5, down from $69.00, indicating a 6.52% decrease. Analysts from firms including RBC Capital, B of A Securities, Cantor Fitzgerald, and Deutsche Bank have updated their ratings and price targets, reflecting changes in market conditions and company performance. Prothena Corp, a biotechnology company, has shown significant revenue growth and strong financial performance, with a revenue growth rate of 5494.33% as of September 30, 2023, and a net margin of 25.81%.
February 16, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Prothena Corp received mixed analyst ratings, with a downward adjustment in the average 12-month price target to $64.5, indicating a cautious outlook. The company has demonstrated significant revenue growth and strong financial performance.
The mixed analyst ratings and the decrease in the average price target suggest a cautious but not negative outlook for Prothena Corp. The significant revenue growth and strong financial indicators, such as net margin and ROE, support a stable short-term performance. However, the adjustments in analyst ratings and price targets indicate uncertainty in future performance, leading to a neutral score.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100